Question 1

Which UAE healthcare regulator do I need?

Accepted Answer

Three primary regulators plus free-zone health authorities. (1) Dubai Health Authority (DHA) — licenses healthcare facilities and professionals in mainland Dubai under the Dubai Health Strategy framework. (2) Department of Health Abu Dhabi (DOH) — licenses Abu Dhabi healthcare facilities and professionals. (3) Ministry of Health and Prevention (MOHAP) — federal regulator covering Northern Emirates, plus federal-level matters (drug registration, medical device registration, telemedicine cross-emirate framework, healthcare professional federal registry). (4) Free-zone health authorities — DHCC (Dubai Healthcare City Authority) for DHCC-located facilities; IHC (International Humanitarian City) for humanitarian operations; ADHC (Abu Dhabi Healthcare City) for Abu Dhabi free zones. The Emirates Drug Establishment (EDE), formed in 2024, is the federal pharmaceuticals regulator (replacing the historical MOHAP drug-control function).

Question 2

How do I license a hospital or clinic?

Accepted Answer

Process varies by emirate but follows a common arc. (i) Initial Approval — facility owner files application with the relevant regulator (DHA / DOH / MOHAP) including business plan, premises plans (which must comply with regulator-specified facility design standards), professional staffing plan, equipment list, scope of services. (ii) Premises construction or fit-out per the approved plans, with regulator inspections at milestones. (iii) Equipment certification — medical-device registration with the regulator (or referenced from EDE registration). (iv) Professional licensing — every doctor, nurse and allied-health professional must hold individual practitioner licence (DHA / DOH / MOHAP), typically following Prometric or similar exam plus credential verification. (v) Final inspection and operational licence issuance. (vi) Insurance — mandatory professional indemnity per regulator standards. Realistic timeline: 6-18 months for a clinic; 18-36 months for a hospital.

Question 3

How is telemedicine regulated?

Accepted Answer

MOHAP issued the federal Telemedicine Standards in 2024 (replacing the 2018 framework), with DHA and DOH operating aligned but separately enforced standards. Key requirements: (i) the telemedicine practitioner must hold a UAE practitioner licence (DHA / DOH / MOHAP, depending on the patient's emirate); (ii) cross-border telemedicine into the UAE by foreign-licensed practitioners is permitted only via specific reciprocity arrangements (none currently in place except for emergency consultations); (iii) prescriptions issued via telemedicine are valid subject to specific dispensing rules; (iv) data protection (PDPL + sectoral health-data overlay) applies to all consultations; (v) facility licensing for the telemedicine platform itself (not just the practitioner). Cross-emirate telemedicine within the UAE was streamlined in the 2024 standards but still requires careful navigation.

Question 4

What about medical malpractice?

Accepted Answer

Federal Decree-Law 4 of 2016 (the UAE Medical Liability Law) is the federal medical-liability framework, with implementing regulations through Ministerial Decisions and the regulator-specific procedures. Process: (i) patient complaint to the relevant regulator (DHA / DOH / MOHAP); (ii) Medical Liability Committee review with technical experts; (iii) decision on whether medical error occurred; (iv) civil claim available in parallel for damages; (v) criminal referral possible in cases of gross negligence. Mandatory professional indemnity insurance covers most claims but not always at adequate limits. We act for both patients and providers — early Medical Liability Committee strategy is decisive.

Question 5

How do I register a medical device or pharmaceutical?

Accepted Answer

The Emirates Drug Establishment (EDE), established 2024, is the federal pharmaceuticals and medical-device regulator. Pharmaceutical registration: standard EDE submission with chemistry-manufacturing-controls, clinical safety/efficacy data, GMP certification, pricing approval, ICD-10/MCBC coding. Average timeline: 12-24 months for new active ingredients; faster for generic / biosimilar with reference product approved abroad. Medical device registration: classified by risk class (I, IIa, IIb, III), submission with technical documentation, performance evaluation, CE/FDA recognition (sometimes accepted as fast-track basis), clinical evaluation. EDE has mutual recognition arrangements with select foreign regulators (FDA, EMA, MHRA, TGA, Health Canada, Swissmedic) under specific conditions.

Question 6

What about clinical trials in the UAE?

Accepted Answer

Clinical trials require approval from EDE (federal) plus the relevant emirate-level Ethics Committee approval (DHA REC, DOH REC, MOHAP REC depending on emirate; or institutional REC at academic centres). UAE has been actively positioning as a regional clinical-trials hub through the National Clinical Trials Initiative. Process: (i) Sponsor application with protocol, IB, IMP details, insurance; (ii) EDE review (~3 months); (iii) Ethics Committee review in parallel (~2 months); (iv) Site activation; (v) Ongoing pharmacovigilance reporting. Cross-border manufactured IMPs require EDE import authorisation. The DIFC Healthcare offers a separate framework for some clinical trials.

UAE Healthcare & Life Sciences — DHA, DOH, MOHAP, EDE.

What we do for healthcare providers, life-sciences companies and pharmacies.

Facility & professional licensing

Pharma & devices (EDE)

Clinical trials & research

Disputes & defence

Frequently asked questions

Healthcare matter on your desk?